SIRT1 and osteosarcoma: Since NNMT-driven SIRT1 activation could potentially counteract HDAC inhibition, future studies should explore whether NNMT inhibitors could enhance the therapeutic efficacy of HDAC inhibitors in osteosarcoma treatment.